NSEAnalysts/Institutional Investor Meet/Con. Call Updates5 Aug 2026 · 5 Aug 2026, 07:05 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Akums Drugs and Pharmaceuticals Limited · AKUMS
✦ AI SummaryResults
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts conference call for Q1 FY 27 un-audited financial results.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
NSEAKUMS10_05082026190449_AKUMSEARNINGCALLINTIMATION.pdf
View document text
Ref: Akums/Exchange/2026-27/36 August 05, 2026
To, To,
The Listing Department The Listing Department
National Stock Exchange of India Ltd BSE Limited
Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring,
Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy
Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001
Symbol: AKUMS Scrip Code: 544222
Sub: Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un-
audited financial results of Q1 FY 27
Respected Sir/Ma’am,
This is to inform you that pursuant to regulation 30 read with Part A of Schedule III of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals
Limited will be hosting below scheduled investor/analysts conference call (group meet):
S. No. Particulars of Date of Meeting Type of Location / Mode
Meet Meet of Meeting
1 Earning/Quarterly 10th August, 2026 Group meet Virtual
Calls Starts at 12:00 PM (IST)
Please find enclosed Dial-in details for the same.
Further, no unpublished price sensitive information pertaining to the Company will be shared during
the meet with Analysts/Investors.
Please note that the above may subject to change due to exigencies on the part of Investors/analysts
or Company.
A copy of this disclosure is being updated on website of the Company at www.akums.in
This is for your information and records.
For Akums Drugs and Pharmaceuticals Limited
Dharamvir Malik
Company Secretary & Compliance Officer
Encl: As above
Q1FY27 Earnings Call
Akums Drugs & Pharmaceuticals
August 10, 2026 at 12:00 pm (IST)
Ambit Capital cordially invites you to the Q1FY27 Earnings Call of Akums Drugs & Pharmaceuticals
Company Representatives
Mr. Sanjeev Jain – Managing Director
Mr. Sandeep Jain – Managing Director
Mr. Sumeet Sood – Chief Financial Officer
Mr. Sahil Maheshwari – Head Strategy
The teleconference will be moderated by Umesh Laddha, Institutional Equities, Ambit Capital.
Conference Call Details
Date: August 10, 2026 | Time: 12:00 pm (IST)
Please join the conference via Diamond Pass to avoid wait time. Please click here to register.
+91 22 6280 1148
Primary Access Numbers
+91 22 7115 8049
Singapore: 800 101 2045
Hong Kong: 800 964 448
International Toll Free Numbers
USA: 1 866 746 2133
UK: 0 808 101 1573
We request you to dial in a few minutes prior to the scheduled time.